Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

Summit Therapeutics (SMMT) stock received a new buy rating from Truist based on its deal-forming prospects in oncology. Read ...

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

GARDASIL is the first HPV vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese males ...

Truist has downgraded Merck (NYSE:MRK) to hold from buy, citing upcoming loss of market exclusivity and continuing headwinds ...

The stock's fall snapped a two-day winning streak.

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...